Last reviewed · How we verify
NCT03792659
The EXPLORE MG Registry for Myasthenia Gravis
Recruiting now
Last updated 28 November 2025
What this trial tests
trial testing Blood Sample Draw in Myasthenia Gravis in 800 participants. Currently enrolling.
Timeline
30 March 2016
Primary endpoint
30 September 2026
30 September 2026
30 October 2026
Quick facts
| Lead sponsor | Yale University |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 800 |
| Start date | 30 March 2016 |
| Primary completion | 30 September 2026 |
| Estimated completion | 30 October 2026 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Blood Sample Draw
Conditions studied
- Myasthenia Gravis — all drugs for Myasthenia Gravis →
Sponsor
Yale University
Who can join
18 and older, any sex, with Myasthenia Gravis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to create a Yale University Department of Neurology Myasthenia Gravis (MG) registry that will be used for current and future research projects involving the study of Myasthenia Gravis.
Publications & conference data
8 peer-reviewed publications reference this trial (live from Europe PMC):
-
Heterogeneity of Acetylcholine Receptor Autoantibody-Mediated Complement Activity in Patients With Myasthenia Gravis.
Obaid AH, Zografou C, Vadysirisack DD, Munro-Sheldon B, et al · · 2022 · cited 44× · PMID 35473886 · DOI 10.1212/nxi.0000000000001169 -
MOGAD patient autoantibodies induce complement, phagocytosis, and cellular cytotoxicity.
Yandamuri SS, Filipek B, Obaid AH, Lele N, et al · · 2023 · cited 34× · PMID 37097758 · DOI 10.1172/jci.insight.165373 -
Reemergence of pathogenic, autoantibody-producing B cell clones in myasthenia gravis following B cell depletion therapy.
Fichtner ML, Hoehn KB, Ford EE, Mane-Damas M, et al · · 2022 · cited 29× · PMID 36307868 · DOI 10.1186/s40478-022-01454-0 -
Exploring outcomes and characteristics of myasthenia gravis: Rationale, aims and design of registry - The EXPLORE-MG registry.
Anil R, Kumar A, Alaparthi S, Sharma A, et al · · 2020 · cited 24× · PMID 32388060 · DOI 10.1016/j.jns.2020.116830 -
The clinical need for clustered AChR cell-based assay testing of seronegative MG.
Masi G, Li Y, Karatz T, Pham MC, et al · · 2022 · cited 20× · PMID 35366559 · DOI 10.1016/j.jneuroim.2022.577850 -
Elevated N-Linked Glycosylation of IgG V Regions in Myasthenia Gravis Disease Subtypes.
Mandel-Brehm C, Fichtner ML, Jiang R, Winton VJ, et al · · 2021 · cited 19× · PMID 34544801 · DOI 10.4049/jimmunol.2100225 -
Myasthenia gravis complement activity is independent of autoantibody titer and disease severity.
Fichtner ML, Hoarty MD, Vadysirisack DD, Munro-Sheldon B, et al · · 2022 · cited 9× · PMID 35290370 · DOI 10.1371/journal.pone.0264489 -
A Noncanonical CD56dimCD16dim/- NK Cell Subset Indicative of Prior Cytotoxic Activity Is Elevated in Patients with Autoantibody-Mediated Neurologic Diseases.
Yandamuri SS, Filipek B, Lele N, Cohen I, et al · · 2024 · cited 6× · PMID 38251887 · DOI 10.4049/jimmunol.2300015
Verify or expand the search:
- PubMed search for NCT03792659
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Myasthenia Gravis
Currently open trials in the same condition.
- NCT07478172 — Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease · NA · recruiting
- NCT07217587 — Comparative Efficacy of Nipocalimab and Efgartigimod in Participants With Generalized Myasthenia Gravis · Phase 3 · recruiting
- NCT07284420 — ADAPT Forward 1 - ISA1 - a Study to Evaluate Empasiprubart IV as add-on Therapy to Efgartigimod IV in Participants With · Phase 2 · recruiting
- NCT07294170 — ADAPT Forward - Master Protocol of a Platform Study to Evaluate the Safety and Efficacy of Multiple Regimens in Particip · recruiting
- NCT07246564 — Phase 4 Study Evaluating Efficacy and Safety of Rozanolixizumab in Adult Chinese Participants With Generalized Myastheni · Phase 4 · recruiting
Other Yale University trials
Trials by the same sponsor.
- NCT06900998 — Pilot Study: Effects of Nimodipine on Alcohol Drinking · Phase 2 · not yet recruiting
- NCT04910984 — Developing a Chatbot to Promote HIV Testing · NA · not yet recruiting
- NCT07458087 — Accuracy of the Accuro 3S · NA · not yet recruiting
- NCT07398404 — A Multiple Health Behavior Change (MHBC) Intervention for Weight Loss and Smoking Cessation for Pre-Bariatric Surgery Pa · Phase 1, PHASE2 · not yet recruiting
- NCT07305324 — Improving Liver Fibrosis Diagnosis in Primary Care Using FibroX AI · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT03792659 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Yale University
- Last refreshed: 28 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03792659.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing